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Summary 
RILP is a downstream effector of the Rab7 GTPase. GTP-bound Rab7 recruits RILP 
on endosomal membranes and, together, they control late endocytic traffic, 
phagosome and autophagosome maturation and are responsible for signaling receptor 
degradation. We have identified, using different approaches, the V1G1 subunit of the 
vacuolar ATPase (V-ATPase) as a RILP interacting protein. V1G1 is a component of 
the peripheral stalk and it is fundamental for correct V-ATPase assembly. We 
established that RILP regulates the recruitment of V1G1 subunit to late 
endosomal/lysosomal membranes but also controls V1G1 stability. Indeed, we 
demonstrated that V1G1 is ubiquitinated and that RILP is responsible for proteasomal 
degradation of V1G1. Furthermore, we demonstrated that alterations of V1G1 
expression levels impair V-ATPase activity. Thus, our data demonstrate for the first 
time that RILP regulates the activity of the V-ATPase through the interaction with 
V1G1. Given the importance of V-ATPase in several cellular processes and human 
diseases, these data suggest that modulation of RILP activity could be used to control 
V-ATPase function. 
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Introduction 
Vacuolar-type H+ ATPases (V-ATPases) are large multi-subunit complexes that 
control acidity of intracellular compartments and are also responsible for proton 
transport across the plasma membrane and thus for acidification of the extracellular 
environment (Forgac, 2007; Sun-Wada et al., 2004; Toei et al., 2010). They are 
proton pumps conserved in all eukaryotes, and organized into two-domains that 
constitute a rotary machine (Cipriano et al., 2008; Kane, 2006; Kane and Smardon, 
2003). V0 is the integral transmembrane domain responsible for proton translocation, 
while V1 is the peripheral domain located in the cytoplasmic site of the membrane 
and it is responsible for ATP hydrolysis providing energy to pump the protons 
(Cipriano et al., 2008; Kane, 2006; Kane and Smardon, 2003). Accurate control of pH 
of intracellular organelles and extracellular milieu is fundamental for many cellular 
processes as, for instance, processing and degradation of macromolecules in secretory 
and digestive compartments, coupled transport of small molecules as neurotrasmitters, 
but also sperm maturation and osteoclast function. Defects in acidification have been 
recently recognized as an important cause of several severe human diseases as renal 
tubule acidosis, osteopetrosis, defects in sperm maturation and diabetes (Casey et al., 
2010; Marshansky and Futai, 2008). In addition, V-ATPase activity regulates 
membrane fusion, early to late endosomal trafficking, and neurosecretion (El Far and 
Seagar, 2011; Hurtado-Lorenzo et al., 2006; Qiu, 2012). Importantly, V-ATPases 
contribute to invasive properties of tumor cells (Forgac, 2007; Sennoune et al., 
2004b). In tumor cells V-ATPases are targeted to the plasma membrane and acidify 
the extracellular environment, activating lysosomal enzymes that are responsible for 
the degradation of extracellular matrix. Thus V-ATPases are directly involved in 
invasiveness, also of endothelial cells during angiogenesis, and are now considered a 
very promising target against metastasis (Forgac, 2007). 
The reversible dissociation of the complex into the V1 and V0 domain 
represent a fundamental control mechanism of V-ATPase function that is responsible 
for varying rates of pumping (Forgac, 2007). However, also reversible dissociation of 
single subunits has been reported to regulate V-ATPase activity (Qi et al., 2007). A 
complex named RAVE regulates pumps assembly (Smardon et al., 2002). In addition, 
also extracellular pH regulates strongly V-ATPase activity and assembly (Diakov and 
Kane, 2010). 
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RILP (Rab Interacting Lysosomal Protein) is an effector of the small GTPase 
Rab7 (Cantalupo et al., 2001; Bucci et al. 1988; Chavrier et al. 1990). Rab proteins 
localize to the cytosolic side of intracellular organelles and regulate membrane traffic 
(Aloisi and Bucci, 2013; Bucci and Chiariello, 2006; Stenmark, 2009). Rab7, in its 
active GTP-bound form, recruits RILP on membrane and together they control 
trafficking to late endosomes and lysosomes in the endocytic route (Bucci et al., 2000; 
Cantalupo et al., 2001; Jordens et al., 2001). Furthermore, RILP is involved in the 
biogenesis of multivesicular bodies (Progida et al., 2007; Progida et al., 2006). 
Using the two-hybrid system, we have isolated the V1G1 subunit of V-
ATPase as a RILP interacting protein. Our data indicate that RILP, through its direct 
interaction with V1G1, regulates the function of V-ATPase. Thus, we have discovered 
a new regulatory mechanism of V-ATPase function, and, given the involvement of V-
ATPase in several human diseases, these data suggest that RILP could become a 
useful target for development of effective therapeutical means. 
 
Results 
 
RILP interacts with the V1G1 subunit of the V-ATPase 
A yeast two-hybrid screen was used to identify proteins that interact with RILP. A 
Gal4-binding domain/RILP fusion construct was made in pGBKT7 vector and used in 
the screen to identify putative interactors. The construct was used to screen a liver 
cDNA library encoding proteins as C-terminal fusions with the transcriptional 
activation domain of Gal4 in the pACT2 vector. From 1,3 x 106 primary trasformants, 
27 were His+LacZ+ and were encoding true positives that did not activate transcription 
in the presence of a non-specific test bait. Seven transformants encoded the entire 
V1G1 subunit of the vacuolar ATPase. The interaction was revealed by the growth of 
yeast cells expressing RILP and V1G1 on synthetic medium lacking histidine and 
adenine. In the two-hybrid system the interaction was specific as the yeasts expressing 
V1G1 together with Rab7 were not able to grow without histidine, or without 
histidine and adenine (Fig. S1A). These results were confirmed using the other 
reporter gene, β-galactosidase (Fig. S1B). Using a β-galactosidase quantitative liquid 
assay, we confirmed the interaction between RILP and V1G1 and established, using 
previously described RILP deletion mutant constructs (Colucci et al., 2005a), that 
V1G1 binds to the N-terminal half of RILP (Fig. S1).   
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To confirm the results obtained with the two-hybrid screen we investigated 
whether the two proteins were able to co-immunoprecipitate. HeLa cells were 
transfected with constructs expressing HA-tagged RILP, V1G1, both or non 
transfected (NT) and immunoprecipitation was performed using an anti-HA resin. 
Immunoprecipitates of HA-tagged RILP contained the V1G1 subunit of V-ATPase 
therefore confirming the interaction (Fig. 1A). In addition, by overexpressing V1G1, 
RILP, RILPC33 and RILPΔC2 we established that V1G1 could be 
immunoprecipitated also by RILPΔC2 but not by RILPC33 (Fig. 1B), thus confirming 
the data obtained with the two-hybrid system indicating that V1G1 binds to the N-
terminal half of RILP (Fig. S1). In order to verify the physiological significance of the 
interaction we also demonstrated co-immunoprecipitation of RILP and V1G1 
endogenous proteins using a crosslink immunoprecipitation kit as described in 
Material and Methods (Fig. 1C). 
Subsequently, to check if the interaction was direct, we purified bacterially 
expressed GST, GST-tagged RILP, GST-tagged RILPC33 and His-tagged V1G1.  
Glutathione resin alone or bound to GST, GST-RILP or GST-RILPC33 was incubated 
with His-tagged V1G1. V1G1 subunit was specifically bound only to GST-tagged 
RILP demonstrating a direct interaction between V1G1 and RILP (Fig. 1D). 
Altogether, these results demonstrate that RILP is able to interact 
physiologically and directly with the V1G1 subunit of the vacuolar ATPase. 
 
RILP interacts simultaneously with V1G1 and p150Glued 
RILP is able also to interact directly with the C-terminal domain of the 
dynactin projecting arm p150Glued, controlling transport of Rab7-positive organelles 
toward the cell center (Cantalupo et al., 2001; Jordens et al., 2011; Johansson et al., 
2007; Harrison et al., 2003). Since acidification of endosomes correlates with their 
translocation toward the microtubule organizing center, we investigated whether the 
interactions of RILP with p150Glued and V1G1 are mutually exclusive. Using purified 
His-V1G1 bound to Ni-NTA resin we were able to pull down FLAG-p150Glued from 
lysates of transfected HeLa cells only in the presence of purified GST-RILP (Fig. 1E). 
These data indicate that RILP can bind at the same time V1G1 and p150Glued.  
 
RILP expression levels affect V1G1 abundance 
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To investigate the role of this interaction we decided to analyze whether modulation 
of RILP expression levels affected V1G1 abundance. Interestingly, upon RILP 
overexpression the total amount of the V1G1 subunit in HeLa cells was reduced (Fig. 
2A). In contrast, in RILP-silenced cells the amount of V1G1 was strongly increased 
(Fig. 2B). Importantly, RILP overexpression or silencing did not affect V1C1 and 
V0D1, two other V-ATPase subunits (Fig. 2A, B) indicating that RILP regulates 
specifically this subunit. Notably, expression of RILPΔC2 or RILPC33 did not affect 
V1G1 abundance (Fig. 2C) suggesting that only the entire protein is able to act on 
V1G1 protein abundance. Furthermore, overexpression of HA-tagged RILP was able 
to partially rescue the effect on V1G1 abundance in RILP-silenced cells thus 
excluding off-target effects (Fig. 2D). 
To establish if the changes observed on V1G1 protein amount were a 
consequence of mRNA abundance, we checked V1G1 mRNA expression using real 
time PCR (Fig. 2G). As expected in cells transfected with HA-RILP, RILP mRNA 
was increased while in RILP-silenced cells, RILP mRNA decreased (Fig. 2E, F). 
Interestingly, we found that the amount of V1G1 mRNA upon RILP overexpression is 
slightly increased while it is decreased upon RILP silencing (Fig. 2G). Thus mRNA 
expression seems to be altered in order to try to counteract the effects on V1G1 
protein amount caused by RILP overexpression or silencing. 
 
RILP induces proteasomal degradation of V1G1 
As we established that RILP expression levels regulate V1G1 amount, we then 
decided to investigate whether RILP was responsible for V1G1 proteasomal 
degradation. We overexpressed RILP and treated cells with the proteasome inhibitor 
MG132. In these conditions the endogenous V1G1 protein level did not decrease 
suggesting that RILP regulates proteasomal degradation of V1G1 (Fig. 2H). We then 
decided to investigate if V1G1 was ubiquitinated. We expressed HA-V1G1 in HeLa 
cells in presence and absence of the proteasomal inhibitor MG132 and in presence or 
absence of RILP overexpression. Lysates of cells were then immunoprecipitated with 
anti-HA resin and subjected to Western blot analysis using an anti-ubiquitin antibody. 
Ubiquitination of V1G1 was present in all samples were HA-V1G1 was expressed 
and immunoprecipitated, but was increased in the presence of MG132 suggesting a 
strong regulation of V1G1 mediated by the proteasome. The V1G1 protein amount 
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decreases upon RILP overexpression while treatment with MG132 partially rescues 
V1G1 levels and strongly increases ubiquitination forms of V1G1. Hence, taking into 
consideration V1G1 levels, RILP overexpression induces V1G1 ubiquitination (Fig. 
2I). 
 
RILP recruits V1G1 on late endosomal/lysosomal membranes 
We then analyzed if RILP is responsible for recruitment of V1G1 on membranes. We 
treated cells with MG132 in order to prevent V1G1 ubiquitin-dependent proteasomal 
degradation induced by RILP and we looked at cytosolic and membrane distribution 
of endogenous V1G1 in control cells and in cells overexpressing RILP. As loading 
controls we used GAPDH, a cytosolic protein, and V0D1, a membrane subunit of V-
ATPase.  Expression of HA-RILP did not change the membrane/cytosol distribution 
of GAPDH and V0D1. The analysis of the distribution of V1G1 showed that the 
amount of membrane-associated V1G1 increased upon RILP overexpression while 
the amount of cytosolic V1G1 decreased (Fig. 3A). Indeed, RILP overexpression 
increased membrane localization of V1G1 of about 30% while cytosolic V1G1 
diminished to 85% compared to control (Fig. 3B). These data demonstrate that, upon 
RILP overexpression, V1G1 membrane localization increases and suggest that RILP 
could recruit V1G1 on endosomal and/or lysosomal membranes.  
Having showed that RILP controls V1G1 amount and recruitment on 
membranes, we decided to investigate whether V1G1 binds to RILP when is in 
complex with other V-ATPase subunits. We immunoprecipitated, using an anti-HA 
resin, HA-tagged RILP from lysates of HeLa cells expressing HA-tagged RILP and 
endogenous or overexpressed V1G1. In both immunoprecipitates we observed the 
presence not only of V1G1 but also of V1C1 and V0D1, two other V-ATPase 
subunits (Fig 3C). Larger amounts of co-immunoprecipitated V1G1, obtained when 
V1G1 was overexpressed, led to increased co-immunoprecipitation of the other two 
subunits (Fig. 3C).  These data suggest that V1G1 interacts with RILP alone or 
complexed with the other subunits thus suggesting that RILP could be important for 
controlling assembly of the entire pump at the endosomal membranes by recruiting 
V1G1.  
We also analyzed by confocal immunofluorescence analysis the intracellular 
localization of V1G1 upon RILP overexpression. As commercially available 
antibodies against the V1G1 subunit of V-ATPase do not work by 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
A
cc
ep
te
d 
m
an
us
cr
ip
t
immunofluorescence we looked at localization of overexpressed HA-tagged V1G1 
subunit. As expected, V1G1 was partially colocalizing with Lamp1 on late endosomal 
and lysosomal structures (Fig. 4). Expression of RILP caused clustering of late 
endosomal and lysosomal structures, as previously reported (Cantalupo et al., 2001; 
Colucci et al., 2005b) and HA-tagged V1G1 was localized onto the clustered 
structures generated and marked by GFP-RILP (Fig. 4A). Interestingly, upon RILP 
overexpression, the colocalization percentage of V1G1 with Lamp1 is increased (Fig. 
4A, B). In contrast, expression of RILP-C33, the deletion mutant containing only the 
C-terminal half of RILP that does not interact with V1G1, decreases colocalization 
with Lamp1 (Fig. 4A, B). These data suggest that localization of V1G1 on late 
endosomal/lysosomal membrane is regulated by RILP. Furthermore HA-tagged V1G1 
partially co-localized with RILP on late endosomal/lysosomal structures labelled with 
Lamp1 while very little co-localization was detected with RILPC33 (Fig. 4A). 
Quantification data (Fig. 4C) indicate that less than 10% of co-localization was found 
between HA-V1G1 and RILPC33, thus confirming the interaction data. 
In addition, we analyzed the effects of RILP silencing on HA-tagged V1G1 
localization (Fig. 5). Interestingly, in RILP-depleted cells (RILPi) the colocalization 
of HA-tagged V1G1 with Lamp1 decreased, thus confirming the role of RILP in 
recruiting V1G1 on late endosomal and lysosomal membranes (Fig. 5). In addition, 
upon RILP silencing, the colocalization of HA-tagged V1G1 with giantin, a marker of 
the Golgi complex, strongly increased indicating that, in the absence of RILP, V1G1 
localizes mainly to other compartments (Fig. 5).  
Altogether these data indicate that RILP recruits V1G1 on late endosomal and 
lysosomal membranes and suggest that RILP could be important for the assembly of 
the pump on these organelles. 
 
RILP is in complex with V1G1 together with Rab7 
RILP is a Rab7 effector protein and, thus, in order to investigate whether Rab7 is also 
involved in the regulation of V1G1 we transiently overexpressed or silenced Rab7 and 
looked at V1G1 abundance (Fig. 6A, B). Interestingly, Rab7 overexpression didn’t 
affect V1G1 abundance while Rab7 silencing caused a strong decrease in the amount 
of V1G1 (Fig. 6A, B).  Furthermore, the decrease of V1G1 amount caused by RILP 
overexpression was counteracted by Rab7 overexpression (Fig. 6C) thus suggesting 
that when RILP binds Rab7 does not induce V1G1 degradation. 
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In order to further investigate the role of Rab7 in the interaction between RILP and 
V1G1 we expressed in HeLa cells HA-RILP, HA-RILPΔC2, HA-RILPC33, Myc-
Rab7, and V1G1 in different combinations and we immunoprecipitated V1G1 using a 
specific anti-V1G1 antibody (Fig. 6D). Immunoprecipitates were then analyzed for 
the presence of the different recombinant proteins. As expected V1G1 was able to co-
immunoprecipitate HA-RILP, HA-RILPΔC2 but not HA-RILPC33 (Fig. 6D, lanes 2-
4). Interestingly, V1G1 was also able to co-immunoprecipitate Rab7 (Fig. 6D, lane 5) 
although in the two-hybrid system we did not detect interaction between these two 
proteins (Fig. S1). However, coimmunoprecipitation of V1G1 and Rab7 was seen 
both upon exogenous HA-RILP expression (Fig. 6D, lane 7) and in the presence of 
endogenous RILP (Fig. 6D, lane 5). In RILP-silenced cells Rab7 was not anymore co-
immunoprecipitating with V1G1 (Fig. 6D, lane 6). These data indicate that V1G1 
does not interact directly with Rab7 and that RILP is able to interact simultaneously 
with Rab7 and V1G1. Indeed, expression of RILP truncated forms RILPΔC2 or 
RILPC33, binding to and sequestering V1G1 and Rab7 respectively, abolished the co-
immunoprecipitation of Rab7 (Fig. 6D, 12-13).  
Altogether these data indicate that Rab7 recruits on endolysosomal 
membranes RILP that in turn recruit V1G1, while RILP induces V1G1 proteasomal 
degradation when it is not bound to Rab7. 
 
V-ATPase activity is regulated by RILP 
RILP is required for biogenesis of multivesicular bodies (MVBs) and, together with 
Rab7, regulates late endocytic traffic (Progida et al., 2007). Acidification, triggered by 
V-ATPase, is required for the formation of MVBs (Aniento et al., 1996; Clague et al., 
1994; Marshansky and Futai, 2008; Trajkovic et al., 2008). Thus RILP might 
coordinate the biogenesis of MVBs through V-ATPase activity regulation, by 
controlling V1G1 amount and localization. In order to investigate if RILP influence 
V-ATPase activity we used LysoTracker Red, a marker of acidic compartments that 
stains vesicles with an internal pH of less than 6.5, in HeLa cells depleted of RILP 
(RILPi) (Fig. 7A). The samples were analyzed by live microscopy and LysoTracker 
Red intensity in RILPi samples relative to control (scr) was quantified (Fig. 7B). 
Interestingly, the levels of LysoTracker Red intensity increased more than twice in 
RILPi cells, suggesting a role of RILP in controlling V-ATPase activity (Fig. 7A, B). 
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Furthermore, the distribution of acidic compartments was more diffuse and peripheral 
in RILP-depleted cells compared to control cells (scr). 
 
V1G1 is fundamental for V-ATPase activity 
Since we have demonstrated that RILP is important for acidification and controls 
V1G1 abundance and recruitment on late endosomal and lysosomal membranes, we 
decided to investigate the relevance of V1G1 on V-ATPase activity. In order to 
monitor how variations of V1G1 abundance affect V-ATPase activity, we monitored 
cathepsin D maturation in HeLa cells overexpressing V1G1 or silenced for V1G1 
both transiently and stably. Cathepsin D is synthesized as preprocathepsin-D 
precursor, which is converted into procathepsin D (52 kDa) in the endoplasmic 
reticulum (ER) and then it undergoes further proteolytic processing, in the acidic 
milieu of late endosomes and lysosomes, being converted in a 44-kDa form and 
finally into the 32-kDa mature form. Lysates of control HeLa cells, of V1G1-silenced 
or of V1G1 overexpressing cells were subjected to Western blot analysis with an anti-
cathepsin D antibody able to recognize the 52 kDa, the 44 kDa and the 32 kDa forms 
(Fig. 7C). In control cells the 52 kDa and the 44 kDa represented less than 30% of the 
total cathepsin D staining while, as expected, treatment with the high affinity inhibitor 
of V-ATPase bafilomycin A1 caused the accumulation of the immature forms and 
reduced the amount of the mature 32 kDa form to less than 5% (Fig. 7C, D). Transient 
or stable overexpression (in two independent clones) of V1G1 caused a strong 
increase in the amount of immature cathepsin D forms while the mature 32 kDa form 
represented less than 25% of the total cathepsin D staining (Fig. 7C, D). Similarly, 
transient or stable depletion of V1G1 (in two independent clones) caused an 
accumulation of the immature forms while the mature cathepsin D 32 kDa form was 
less then 25% of the total cathepsin D staining (Fig. 7C, D). In contrast, no changes 
were detected in cells transfected with a construct expressing a control sh-RNA (Fig. 
7C, D). 
As V1G1 seems to be important to ensure a proper V-ATPase activity, we 
wanted to investigate the effect on late endosomes and lysosomes when cells were 
depleted of V1G1. We therefore used two different markers of acidic compartments: 
LysoTracker Red (that accumulates in acidic compartments) and LysoSensor DND-
192 (that labels less acidic compartments than LysoTracker Red) and we internalized 
fluorescently labeled transferrin in HeLa cells stable depleted of V1G1 (in two 
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independent clones). Afterwards, we quantified the relative amount of transferrin 
colocalizing with LysoTracker Red or LysoSensor-positive endosomes, by confocal 
microscopy analysis (Fig. S2). Transferrin labels mainly sorting and recycling early 
endosomes and only a little percentage of it reach late endosomes and lysosomes to be 
degraded (Dautry-Varsat et al., 1983; Hopkins and Trowbridge, 1983). Changes in the 
percentage of transferrin colocalizing with endocytic degradative compartments 
represent a clear indication of alteration of the endocytic route (Roxrud et al., 2009). 
The levels of transferrin in LysoTracker-positive structures increased in both clones 
depleted of V1G1, and the increase was stronger in LysoSensor-positive endosomes 
(Fig. S2). These results confirm the importance of V1G1 for the V-ATPase activity, 
as the depletion of this subunit causes accumulation of transferrin in acidic 
compartments, suggesting impaired degradation, and thus malfunctioning of late 
endosomes and lysosomes. 
Altogether, these data demonstrate that changes in the amount of V1G1 impair 
V-ATPase activity. 
 
Discussion 
V-ATPases are highly conserved enzymes that couple ATP hydrolysis to 
proton transport across membranes, are constituted by two domains and multiple 
subunits and are localized to the membrane of several organelles (Cipriano et al., 
2008; Toei et al., 2010). The G subunit of the V-ATPase V1 domain is part, together 
with the E subunit, of the peripheral stator stalks responsible for structurally and 
functionally linking the peripheral V1 sector to the membrane VO sector of the pump 
(Armbrüster et al., 2003; Ohira et al., 2006). There are two isoforms of the G subunit: 
G1 is ubiquitously distributed while G2 is specifically localized in central nervous 
system neurons (Murata et al., 2002). We have identified the G1 subunit of V-ATPase 
as a RILP interacting protein. We proved that the interaction is physiological as it was 
detected by co-immunoprecipitation of overexpressed (Fig. 1A) but also endogenous 
proteins (Fig. 1C). Furthermore, we proved that the interaction is direct, as it was 
detectable also between bacterially expressed and purified proteins (Fig. 1D). In 
addition, our data indicate that V1G1 interacts with the N-terminal half of RILP (Fig. 
1, 6D, S1,) in contrast to Rab7 that binds in the C-terminal half of RILP (Cantalupo et 
al., 2001). Interestingly, the complex RILP-V1G1 can interact with the dynactin 
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projecting arm p150Glued (Fig. 1E), suggesting that RILP could control simultaneously 
endosomes acidification and translocation toward the microtubule organizing center. 
 
Which is the functional meaning of this interaction? 
Our data indicate that RILP regulates recruitment of V1G1 on endosomes and 
lysosomes. Overexpression of RILP increases colocalization of V1G1 with the late 
endosomal/lysosomal marker Lamp1 while expression of the RILPC33 mutant, 
unable to bind V1G1, decreases it (Fig. 4). In addition, overexpression of RILP 
increases the amount of V1G1 present in membranes and drastically decreases V1G1 
in the cytosol (Fig. 3A, B). In agreement, in RILP-silenced cells colocalization of 
V1G1 with Lamp1 decreases while co-localization with giantin increases (Fig. 5) 
indicating that RILP is important for recruitment of V1G1 on late endosomal and 
lysosomal membranes. Thus, GTP-bound Rab7 recruits RILP on late endosomes and 
lysosomes (Cantalupo et al., 2001) and RILP, in turn, recruits V1G1 on these 
organelles. In fact, we demonstrated by co-immunoprecipitation that RILP is able to 
bind simultaneously V1G1 at its N-terminal half and Rab7 at its C-terminal half (Fig. 
6D). Also we established that V1G1 is not able to bind directly Rab7 since V1G1 is 
not able to interact with Rab7 in the two-hybrid system (Fig. S1) and it is not able to 
co-immunoprecipitate Rab7 in the absence of RILP (Fig. 6D).  
As V1G1 is important for V-ATPase assembly and function (Ohira et al., 
2006; Tomashek et al., 1997), the recruitment of V1G1 on endosomal/lysosomal 
membranes is likely to contribute to the correct assembly and, consequently, 
functioning of the pump. In fact our data show that V1G1, when binding to RILP, can 
be also in complex with other subunits of the cytosolic and membrane domain of V-
ATPase (Fig. 3C), thus suggesting that RILP could control not only recruitment of 
V1G1 on endosomal and lysosomal membranes but also the assembly of the entire 
pump. Furthermore, we demonstrated that RILP modulates the activity of the pump 
on late endosomes and lysosomes controlling V1G1 localization (Fig. 4, 5). Indeed, in 
RILP-depleted cells we detected mislocalization of the V1G1 on other organelles 
(Fig. 5) and a different intracellular distribution and higher intensity of LysoTracker 
Red (Fig. 7A-B). These data, together with the previously reported inhibition of 
EGFR degradation and increase of Lamp levels upon RILP silencing (Progida et al., 
2006; Progida et al., 2007), suggest a block of endosomal maturation caused by the 
failed recruitment of the proton pump on Rab7-labeled endosomes.  
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We have shown previously that RILP is important for MVBs formation 
(Progida et al., 2007; Progida et al., 2006). As MVBs formation is dependent on the 
luminal acidic pH of endosomes and thus on the acidification triggered by V-ATPase 
(Aniento et al., 1996; Clague et al., 1994; Marshansky and Futai, 2008; Trajkovic et 
al., 2008), our data support the idea that RILP might coordinate the biogenesis of 
MVBs through V1G1 activity regulation. 
Our data demonstrate also that RILP regulates V1G1 subunit abundance. 
Overexpression of RILP causes a reduction of V1G1 amount while in RILP-silenced 
cells the V1G1 amount is strongly increased (Fig. 2A, B). Furthermore, we 
established that RILP induces V1G1 ubiquitination-dependent proteasomal 
degradation (Fig. 2I). Thus, RILP promotes recruitment of V1G1 on endosomal 
membranes but also induces V1G1 degradation. How are these two different and 
contrasting functions regulated? Our data indicate that overexpression of Rab7 has no 
effect on V1G1 abundance while Rab7 silencing causes a strong V1G1 decrease (Fig. 
6A, B). Hence these data suggest that when RILP is bound to Rab7 recruits V1G1 on 
membranes, while an excess of RILP unbound to Rab7 (as in the case of RILP 
overexpression or of Rab7 silencing) leads to V1G1 degradation. Therefore, the 
amount of V1G1 is strictly regulated by the availability of cytosolic RILP. 
Previously, we have observed that expression of the Rab7T22N mutant, which 
is unable to recruit RILP on late endosomal/lysosomal membranes, causes a strong 
decrease in LysoTracker Red staining (Bucci et al., 2000), thus indicating an increase 
in pH of intracellular organelles, possibly caused by impaired V-ATPase assembly 
and function due to the lack of recruitment of V1G1 mediated by RILP.  These data 
seem in contrast with the fact that RILP silencing causes an increase of LysoTracker 
intensity (Fig. 7A, B). However, in cells expressing the Rab7T22N mutant, RILP is 
still present but it can’t be recruited on endosomes and could, instead, induce V1G1 
degradation. 
We also demonstrated that a proper amount of V1G1 seems to be fundamental 
for the correct functioning of the pump. Overexpression or silencing of V1G1 subunit 
causes a strong inhibition of cathepsin D maturation similarly to what happens 
treating the cells with BafilomycinA1, a inhibitor of the vacuolar pump (Fig. 7C, D). 
Moreover, V1G1 silencing causes accumulation of transferrin in acidic compartments 
suggesting malfunctioning of late endosomes and lysosomes (Fig. S2). These data are 
in agreement with previously published data suggesting that changes in V1G1 
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expression destabilizes the E subunit influencing V-ATPase assembly (Ohira et al., 
2006; Tomashek et al., 1997). The V1G1 subunit thus seems to be a crucial subunit 
not only for correct assembly of the vacuolar pump but also for V-ATPase function as 
changes in V1G1 amounts have strong negative effects on processes regulated by V-
ATPase. 
The discovery of the interaction between RILP and V1G1 is of importance as 
it reveals a new mechanism of regulation of the V-ATPase mediated by RILP. In 
particular, our data demonstrate that RILP regulates V1G1 abundance and it is crucial 
for the regulation of V-ATPase at the level of late endosomes and lysosomes 
promoting assembly and activation of the proton pump on these organelles (Fig. 8). 
V-ATPase has been proposed as a drug target for several diseases and 
processes (Hinton et al., 2009; Kartner and Manolson, 2012). Plasma membrane V-
ATPases are important for sperm maturation and viability (Pietrement et al., 2006), 
for acid secretion of certain kind of renal cells whose malfunctioning causes renal 
tubular acidosis (Karet et al., 1999; Smith et al., 2000), and for osteoclast bone 
degradation (Frattini et al., 2000; Toyomura et al., 2003) that, if altered, causes 
osteopetrosis and osteoporosis. Importantly, in many tumor cell lines V-ATPases are 
abundant in plasma membranes and activity in plasma membranes has been directly 
correlated with invasiveness (Sennoune et al., 2004a; Sennoune et al., 2004b; 
Sennoune and Martinez-Zaguilan, 2012). The tumor acidic microenvironment has a 
key role for tumor development and progression as it influences resistance to 
chemotherapy, proliferation and formation of metastasis (Hernandez et al., 2012). 
Thus, in order to fight cancer, the use of V-ATPase inhibitors and/or the regulation of 
V-ATPase assembly have been proposed to control V-ATPase activity (Kane, 2012; 
Pérez-Sayáns et al., 2009). Our data suggest that modulation of RILP expression 
could represent a mechanism to regulate V-ATPase activity. Furthermore, the 
discovery of the functional link between RILP and V-ATPase opens new scenarios on 
the cellular role of RILP that will have to be further investigated. 
 
Materials and methods 
 
Cells and reagents 
Restriction and modification enzymes were from New England Biolabs (Ipswich, 
MA), chemicals were from Sigma-Aldrich (St Luis, MO), while tissue culture 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
A
cc
ep
te
d 
m
an
us
cr
ip
t
reagents were from Sigma-Aldrich or Invitrogen (Carlsbad, CA). HeLa cells were 
grown in DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin 
and 10 mg/ml streptomycin, in a 5% CO2 incubator at 37°C. HeLa cells were also 
stably transfected with pCDNA3_2xHA_V1G1 plasmid or stably silenced using the 
sh-RNA V1G1 plasmids (sc-36797-SH, Santa Cruz Biotechnology, Santa Cruz, CA). 
Stable cell lines were selected adding G-418 (1mg/ml, Calbiochem, Darmstadt, 
Germany) to cells transfected with pCDNA3_2xHA_V1G1 plasmid or Puromycin 
(3μg/ml, Sigma-Aldrich) to V1G1- silenced cells. When indicated MG132 (10μM, 
C2211 Sigma-Aldrich) was used for 3-5h. 
 
Plasmid construction 
Most Rab7 and RILP constructs used in this study have been described previously 
(Cantalupo et al., 2001; Colucci et al., 2005a; Progida et al., 2006; Vitelli et al., 1997). 
The pCDNA3_2xHA_RILP construct was used to amplify a fragment using the 
following oligonucleotides  5’-
CTTAGAATTCTAATGGAGCCCAGGAGGGCGGCG-3’ and 5’-
ATAAGAATGCGGCCGCTCACCATTCGGGCTCCTGTCCGTGCTG-3’. The 
fragment, coding for the N-terminal half of RILP, was then digested with EcoRI and 
NotI and cloned in the pCDNA3-2xHA vector to obtain a construct for the expression 
of a HA-tagged RILPΔC2. The V1G1 ORF was amplified from the two-hybrid 
pACT2-VIG1 construct using the following oligonucleotides 5’-
CTAAGATCTATGGCTAGTCAGTCTCAGGGG-3’ and 5’-
CGCAAGCTTCTATCCATTTATGCGGTAGTT-3’. The amplified fragment was 
then digested with BglII and HindIII and cloned in the pEGFP-C1 vector to obtain a 
construct for expression of GFP-tagged V1G1. The pCDNA3-V1G1 construct was 
obtained after cloning the BglII-HindIII fragment form the pEGFP-V1G1 in the 
pCDNA3 vector cut with BamHI and HindIII. To obtain the HA-tagged V1G1 an 
EcoRV-XhoI fragment containing the V1G1 ORF was cloned in the pCDNA3_2xHA 
plasmid. The pCMV6-AC-GFP-V1G1 (RG203317) were obtained from Origene 
(Rockville, MD). The pEF-FLAG-p150Glued construct has been previously described 
(Ohbayashi et al., 2012). 
 
Two-hybrid assay 
The construct pGBKT7-RILP was used to screen a human liver cDNA library in the 
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pACT2 vector in AH109 yeast cells (Bartel et al., 1993; Suter et al., 2008). 
Transformants were plated onto synthetic medium lacking His, Leu, and Trp. 
Colonies were picked 5 days later and then assayed for growth on medium lacking 
Ade, His, Leu and Trp and for β-galactosidase activity (Bartel et al., 1993). 
Specificity tests were made transforming AH109 yeast cells with the pGBKT7 vector 
or the pGBKT7-Rab7 construct (as a negative controls) or the pGBKT7-RILP wt 
construct, and with the PGADT7-V1G1 construct. Clones were then assayed for 
growth on selective medium and for β-galactosidase activity using o-nitrophenyl-β-D-
galactoside as a substrate (Bartel et al., 1993). 
 
Transfection and RNA interference 
Transfection was performed using Metafectene Pro or Metafectene Easy from Biontex 
(Martinsried, Germany) following manufacturer’s instructions. After 20 h of 
transfection cells were processed for immunofluorescence or biochemical assays. For 
RNA interference siRNAs were purchased from MWG-Biotech (Ebersberg, 
Germany) or Sigma-Aldrich. We used the following oligonucleotides: siRNA-RILP2, 
sense 5′-GAUCAAGGCCAAGAUGUUATT-3′ and antisense sequence 5′-
UAACAUCUUGGCCUUGAUCTT-3’; control RNA: sense 5’-
ACUUCGAGCGUGCAUGGCUTT-3’and antisense 5’-
AGCCAUGCACGCUCGAAGUTT-3’; siRNA-V1G1, sense 5′-
AGAAGAAGCUCAGGCUGAATT-3′ and antisense sequence 5′-
UUCTGCCTGAGCUUCUUCUTT-3’; siRNA-Rab7a, sense 5′-
GGAUGACCUCUAGGAAGAATT-3′ and antisense sequence 5′-
UUCUUCCUAGAGGUCAUCCTT-3’.  RILP and Rab7 siRNA were efficient in 
silencing as previously reported (De Luca et al., 2008; Progida et al., 2007; Spinosa et 
al., 2008). Briefly, HeLa cells were plated 1 day before transfection in tissue culture 
dishes (6 cm diameter). Cells were transfected with siRNAs using Oligofectamine 
from Invitrogen for 72 h, re-plated and left 48 h before performing further 
experiments.  
 
Antibodies 
Rabbit anti-RILP polyclonal antibodies have been previously described 
(Cantalupo et al., 2001). Goat polyclonal anti-RILP (1:100, sc-82746), rabbit 
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polyclonal anti-RILP (1:100, sc-98331), mouse monoclonal 9E10 anti-Myc (1:500, 
sc-40), rabbit polyclonal and mouse monoclonal anti-HA  (1:500, sc-805 and sc-7392 
respectively), mouse monoclonal anti-V1G1 (1:100, sc-25333), mouse monoclonal 
anti-V0D1 (1:100, sc-81887), goat polyclonal anti-Cathepsin D (1:500, sc-6486) and 
rabbit polyclonal anti-GAPDH (1:10000, sc-25778) antibodies were from Santa Cruz 
Biotechnology.  Rabbit polyclonal anti-V1C1 (1:1000, 361-375), rabbit polyclonal 
anti-Rab7 (1:1000, R4779), mouse monoclonal anti-Rab7 (1:1000, R8779) and mouse 
monoclonal anti-tubulin (1:3000, clone B512) were from Sigma-Aldrich. Chicken 
polyclonal anti-V1G1 (1:1000, ab15853) and rabbit polyclonal anti-Giantin (1:1000, 
ab24586) were from Abcam (Cambridge, UK). Goat polyclonal anti-GST (1:2000, 27-
4577-01) was from GE Healthcare (Buckinghamshire, UK) and rabbit polyclonal anti-
ubiquitin (1:5000, Z0458) was from DAKO (Glostrup Denmark). Mouse monoclonal 
anti-p150 (1:500, 610474) was from BD Bioscience. Secondary antibodies conjugated 
with fluorochromes or HRP were from Invitrogen or SantaCruz Biotechnology.   
 
Membrane-cytosol separation 
For cytosolic and membrane distribution, pellets of HeLa cells were dissolved 
with homogenization buffer (8% sucrose in 3mM imidazole). Cells were passed 
through a 26 gauge needle and centrifuged at 3800g for 5 min a 4°C. The supernant 
(PNS) was centrifuged at 20000rpm for 2h at 4°C and fractionated into high-speed 
pellet (membrane) and supernantant (cytosol). 
 
Co-immunoprecipitation, pull-down and direct interaction experiments 
For immunoprecipitation we used anti-HA affinity gel (Ezview Red Anti-HA 
E6779 from Sigma) accordingly to manufacturer indications and as previously 
described (Cogli et al., 2013b). Co-immunoprecipitation of endogenous proteins in 
HeLa cells was performed using a crosslink immunprecipitation kit (Pierce, Rockford, 
USA) following manufacturer instructions and as previously described (Cogli et al., 
2013a).  
For direct interaction GST, GST-tagged and His-tagged proteins were 
expressed in bacteria and affinity purified as described (Chiariello et al., 1999). 
Glutathione resin alone or bound to purified GST, GST-RILPC33 or GST-RILP was 
incubated with purified His-tagged V1G1 in PBS with 2 mM MgCl2 and GTP 0.8 
mM for 1 h on a rotating wheel. Subsequently, samples were subject to GST pull-
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down using the glutathione resin. Samples were then subjected to SDS-PAGE and 
Western blotting. Pull-down experiments were previously described (Cogli et al., 
2013b). Briefly, purified His-V1G1 was bound to Ni-NTA resin and incubated with 
lysates of HeLa cells transfected with FLAG-p150Glued in the presence or absence of 
purified GST-RILP for 2h at 4oC. In addition, as a control, purified GST-RILP was 
bound to Glutatione resin and incubated with lysates of HeLa cells transfected with 
FLAG-p150Glued for 2h at 4oC. After incubation samples were processed for SDS-
PAGE and Western blot analysis. 
 
Western blotting 
HeLa cells were lysed with RIPA buffer (R0278, Sigma-Aldrich) plus proteinase 
inhibitors cocktail (Roche, Mannheim Germany). For ubiquitination experiments 
RIPA buffer was supplemented with  20 mM Na pyrophosphate pH 7.5, protease 
inhibitors chocktail (Roche), 50 mM NaF, 2 mM PMSF, 10 mM Na vanadate in 
HEPES pH 7.5 and 5 μM NEM (N-ethylmaleimide). Lysates were loaded on SDS-
PAGE and separated proteins were transferred onto PVDF membrane from Millipore 
(Billerica, MA, USA).  
The filter was blocked in 5% milk in PBS for 30 minutes at room temperature, 
incubated with the appropriate antibody and then with a secondary antibody 
conjugated with HRP (diluted 1:5000).  
For anti-ubiquitin incubation, after transferring, filter was subjected to a treatment in 
denaturing solution (6M guanidium chloride, 20 mM Tris pH 7.4, 1 mM PMSF, β-
mercaptoethanol) for 30 minutes at 4ºC, to make proteins more accessible to the 
antibody. After extensive washing in TBS-T buffer (25mM Tris, 150 mM NaCl pH 8, 
Tween 0,05%) the filter was blocked in 5% BSA in TBS (25mM Tris, 150 mM NaCl 
pH 8) for 30 min at room temperature, incubated with the anti-ubiquitin antibody and 
then with a secondary antibody conjugated with HRP (diluted 1:5000). 
Bands were visualized using Western blot Luminol Reagent (Santa Cruz) or 
SuperSignal West Pico (Pierce). 
 
Confocal immunofluorescence microscopy 
Cells grown on 11-mm round glass coverslips were permeabilized, fixed and 
incubated with the antibodies as described previously (Bucci et al., 1992). Cells were 
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viewed with Zeiss LSM 510 confocal microscope. In some experiments cells were 
incubated with LysotrackerRed or LysoSensor DND-192 (Invitrogen) and Alexa647- 
or Alexa555-labelled transferrin (Invitrogen) for 30 min. Cells were imaged by live 
microscopy, and the relative level of transferrin colocalizing with Lysotracker or 
Lysosensor was quantified. 
 
Standard RNA procedures and quantitative real-time PCR 
 Total RNA was extracted from HeLa cells using RNeasy mini kit according to the 
manufacturer’s instructions (Qiagen, Hilden, Germany). The RNA retrotranscription 
protocol was performed as described (Progida et al., 2010). Quantitative real-time 
PCR was performed using SYBR Green JumpStart ReadyMix (Sigma) in the Smart 
Cycler II Real-Time PCR detection system (Cepheid, Sunnyvale, CA, 
USA). The primers used GAPDH Forward: 
5’GGTGGTCTCCTCTGACTTCAACA-3’ Reverse: 5’-
GTTGCTGTAGCCAAATTCGTTGT-3’; V1G1 Forward: 5’-
GCCGAGAAGGTGTCCGAGGCCCG-3’ Reverse: 5’ -
GCGGTACTGTTCAATTTCAGCC-3’; RILP Forward: 5’-
CGGAAGCAGCGGAAGAAGATCAAG-3’ Reverse: 5’-
GAGCAGGATCCATGGGCCAGC-3’ were purchased from Eurofin MWG 
Operon (Ebersberg, Germany) . The PCR programme was as follows: 1 cycle 3 
minutes at 94oC; 35 cycles 30 seconds at 94oC, 30 seconds at 60oC, 30 seconds at 
72oC; 1 cycle 6 minutes at 75oC. The specificity of PCR products was checked by 
performing a melting-curve test. 
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Figure legends 
 
Fig. 1. RILP and V1G1 interact directly. (A) Lysates of control HeLa cells (NT) or 
cells expressing HA-RILP, V1G1 or both were subjected to immunoprecipitation 
using an anti-HA antibody. Lysates (WB) and immunoprecipitates (IP) were 
subjected to Western blot analysis using anti-HA and anti-V1G1 specific antibodies. 
(B) Immunoprecipitates obtained using anti-HA antibodies of control HeLa cells (NT) 
or cells expressing V1G1 and HA-RILP, HA-RILPΔC2 or HA-RILPC33 were 
subjected to Western blot analysis using anti-HA or anti-V1G1 antibody. (C) Total 
extracts of HeLa cells (WB) and immunoprecipitates (IP) obtained with no antibodies 
(no ab), with goat anti-RILP or with goat IgG, as indicated, were subjected to WB 
analysis using chicken anti-V1G1 and rabbit anti-RILP antibodies. (D) Glutathione 
resin alone or bound to purified GST, GST-RILPC33 or GST-RILP was incubated 
with purified His-tagged V1G1. After affinity chromatography proteins were 
subjected to Western blot analysis using anti-GST and anti-V1G1 specific antibodies. 
(E) Bacterially expressed and purified His-tagged V1G1 was incubated with total 
extract of HeLa cells expressing FLAG-p150Glued in the presence or absence of 
purified GST-RILP and pulled-down using Ni-NTA resin. As positive control, GST-
RILP was pulled down after incubation with total extract of HeLa cells expressing 
with FLAG-p150Glued. Proteins were then loaded on SDS-PAGE and subjected to 
Western blot analysis using anti-p150Glued, anti-V1G1 and anti-GST antibodies. 
 
Fig. 2. RILP modulates V1G1 abundance in HeLa cells via ubiquitination-
dependent proteasomal degradation. (A) Lysates of control HeLa cells or cells 
expressing HA-RILP were subjected to Western blot analysis using anti-V1G1, anti-
HA, anti-V1C1, anti-V0D1 and anti-tubulin primary antibodies. (B) Cells treated with 
control RNA (scr), RILP siRNA (RILPi) or V1G1 siRNA (V1G1i) were subjected to 
Western blot analysis using anti-V1G1, anti-RILP, anti-V1C1, anti-V0D1 and anti-
tubulin primary antibodies. (C) Lysates of control HeLa cells (NT) or cells expressing 
HA-RILP, HA-RILPΔC2 or HA-RILPC33 were subjected to Western blot analysis 
using anti-V1G1, anti-HA and anti-tubulin antibodies. (D) Cells treated with control 
RNA (scr), RILP siRNA (RILPi) and transfected with HA-RILP as indicated were 
subjected to Western blot analysis using anti-V1G1, anti-RILP and anti-tubulin 
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antibodies. (E-G) Real Time PCR was performed on control HeLa cells, or cell 
expressing HA-RILP (RILP1 and RILP2) or silenced for RILP (RILPi1 and RILPi2) 
and the amount of RILP (E-F) or of V1G1 (G) was quantified compared to control 
GAPDH RNA transcript.(H) Control cells or cell expressing HA-RILP as indicated 
were untreated or treated with the proteasomal inhibitor MG132. Lysates were then 
subjected to Western blot analysis with V1G1, HA and tubulin antibodies.  (I) Control 
cells or cells transfected with HA-V1G1 and RILP as indicated were untreated or 
treated with MG132. Lysates were subjected to Western blot analysis using anti-
RILP, anti-V1G1 and anti-tubulin antibodies and to immunoprecipitation using anti-
HA antibody. Immunoprecipitates were subjected to Western blot analysis using an 
anti-ubiquitin antibody. 
 
Fig. 3. RILP recruits V1G1 on late endosomal/lysosomal membranes. (A) Post-
nuclear superanatants (PNS), cytosol (C) and membrane (M) fractions of control 
HeLa cells or cells expressing HA-RILP as indicated, treated 3h before harvesting 
with MG132, were subjected to Western blot analysis using anti-V1G1, anti-HA, anti-
V0D1 and anti-GAPDH antibodies. (B) Quantification of the amount of V1G1 present 
in membrane and cytosol normalized for V0D1 and GAPDH, respectively. 
Histograms represents the average (± s.e.m.) of three independent experiments. (C) 
Lysates of control HeLa cells or cells expressing HA-RILP and V1G1 or just HA-
RILP were subjected to immunoprecipitation using mouse anti-HA antibody. Lysates 
(WB) and immunoprecipitates (IP) were subjected to Western blot analysis using anti-
HA, anti-V1G1, anti-V1C1, anti-V0D1 or anti-tubulin specific antibodies.  
 
Fig. 4. RILP partially colocalizes with V1G1 on late endosomal/lysosomal 
organelles. (A) HeLa cells transfected with HA-V1G1 (top panel), co-transfected 
with GFP-RILP and HA-V1G1 (middle panel), or co-transfected with GFP- RILPC33 
and HA-V1G1 (bottom panel), were fixed and immunostained for Lamp1 and HA. 
Bar = 10 μm. (B) Quantification of the colocalization between Lamp1 and V1G1. 
Histogram represents the average (± s.e.m.) of three independent experiments where 
at least 50 cells were quantified per experiment. (C) Quantification of the 
colocalization of V1G1 with GFP-RILP or GFP-RILPC33. Histogram represents the 
average (± s.e.m.) of three independent experiments where at least 50 cells were 
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quantified per experiment.  
 
Fig. 5. RILP depletion affects V1G1 intracellular localization (A) Control (scr) 
and RILP-depleted cells (RILPi) were transfected with HA-V1G1, fixed and 
immunostained for Lamp1, HA and Giantin. Bar = 10 μm. (B) Quantification of the 
colocalization between V1G1 and Lamp1 or V1G1 and Giantin. Histogram represents 
the average (± standard deviation) of three independent experiments where at least 50 
cells were quantified per experiment. 
 
Fig. 6. Role of Rab7 in the regulation of V1G1. Lysates of control HeLa cells (NT) 
or cells expressing HA-Rab7 (A) or of HeLa cells treated with control RNA or Rab7 
siRNA (Rab7i) (B) were subjected to Western blot analysis using anti-V1G1, anti-
Rab7 and anti-tubulin antibodies.  (C) HeLa cells transfected with HA-RILP and HA-
Rab7 as indicated were subjected to Western blot analysis using anti-V1G1, anti-HA 
and anti-tubulin antibodies. (D) Lysates of HeLa cells expressing Myc-Rab7, HA-
RILP, HA-RILPΔC2, HA-RILPC33 and/or V1G1, as indicated, were 
immunoprecipitated using mouse anti-V1G1 antibodies. In one sample RILP was also 
silenced (RILPi) before expression of Myc-Rab7 and V1G1 (lane 6).  
Immunoprecipitates were subjected to Western blot analysis using rabbit anti-Myc, 
rabbit anti-HA and chicken anti-V1G1 antibodies.   
 
Fig. 7. RILP and V1G1 control V-ATPase activity. (A) HeLa cells treated with 
control RNA (scr) or RILP siRNA (RILPi) were incubated with LysoTracker Red for 
30 min and analyzed by live microscopy. (B) The LysoTracker Red intensity, relative 
to scr, was quantified. Histogram represents the average (± standard deviation) of 
three independent experiments where at least 50 cells were quantified per experiment. 
(C) Lysates of control HeLa cells (NT) or cells treated with Bafilomycin A1 or cells 
expressing transiently or stably (clones 1 and 2) HA-V1G1, or expressing transiently 
or stably (clones 1 and 2) sh-V1G1 or  control RNA (sh-C) were subjected to Western 
blot analysis using anti-cathepsin D and anti-tubulin antibodies. (D) Quantification of 
cathepsin D forms. Histogram represents the average (± s.e.m.) of three independent 
experiments. 
 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
A
cc
ep
te
d 
m
an
us
cr
ip
t
Fig. 8. Proposed model for the functional interactions between RILP, V1G1 and 
Rab7. RILP strictly regulates V1G1 abundance and localization promoting activation 
of the proton pump on late endosomes/lysosomes. The binding of RILP to Rab7 
induces V1G1 recruitment on late endosomal/lysosomal membranes and, in turn, 
promotes assembly of the pump on these membranes. In addition the ratio between 
RILP and Rab7 is fundamental for V1G1 protein abundance; an excess of RILP 
unbound to Rab7 (as in the case of RILP overexpression or of Rab7 silencing) leads 
to V1G1 ubiquitination and degradation via a proteasome–dependent mechanism. 
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